Actively Recruiting
Phase 1 Study of GCC2005 with Chemotherapy for Relapsed or Refractory NK and T-cell Malignancies Evaluating Safety, Tolerability, and Early Effectiveness in Adults
Led by GC Cell Corporation · Updated on 2026-07-24
53
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating GCC2005, a CAR-NK cell therapy, in patients with relapsed or refractory CD5-positive NK and T-cell malignancies who have received at least two prior lines of treatment. This Phase 1, first-in-human, single-arm, open-label, multicenter study aims to assess the safety, tolerability, and preliminary effectiveness of GCC2005. The study includes patients with lesions of specific sizes according to the Lugano classification and a performance status of 0 to 2 on the ECOG scale. The study is divided into Phase 1a and Phase 1b parts. Phase 1a focuses on establishing a well-tolerated dose range and safety profile of GCC2005. Phase 1b evaluates safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy after a single administration, reflecting exposure from multiple doses, to optimize the dose and regimen for future studies. Participants receive GCC2005 combined with lymphodepleting chemotherapy consisting of cyclophosphamide and fludarabine. Participants are closely monitored for safety, including the frequency and severity of adverse events up to 18 months after enrollment. Researchers measure the maximum tolerated dose and recommended Phase 2 dose based on safety, efficacy, and pharmacokinetics. The study involves regular assessments of treatment response, toxicity, and pharmacological characteristics. Participants must consent to comply with study procedures and use contraception as required by local regulations.
CONDITIONS
Brief Title
Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies
Research Team
H
HyeSung Jeon
S
Seungryel Han
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here